Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494206 · ClinicalTrials.gov registry record · NA
Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT02494206: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02494206 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02494206, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
Interventions
- DRUG QBX258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494206
The ClinicalTrials.gov registry entry for NCT02494206 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QBX258 is the first listed.
NCT02494206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494206 about?
NCT02494206 is a clinical study titled "Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)". The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
What is the current status of trial NCT02494206?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2015-07. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02494206?
The interventions under investigation include: QBX258 (DRUG).
Who is sponsoring clinical trial NCT02494206?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.